PR.com: Business Directory, Press Releases, Jobs, Products, Services, Articles
 
Businesses Articles Press Releases Follow @PRcom
Press Release Pricing | News by Category | News by Country | News by US Region | Recent News | PR.com News on Your Site
 

Press Releases

 
AnaSpec, EGT Group

Press Release


Receive press releases from AnaSpec, EGT Group: By Email RSS Feeds:

AnaSpec Introduces Industry’s First Suite of MOG Reagents & Assay Kits


AnaSpec is pleased to be the first in the industry to provide a whole suite of reagents and assay kits for the advancement of MS research. This includes MOG proteins, peptides, antibodies and assay kits.

San Jose, CA, July 26, 2009 --(PR.com)-- Myelin Oligodendrocyte Glycoprotein (MOG), a 26- to 28-kDa protein, is a member of the immunoglobulin superfamily. It is expressed exclusively in the central nervous system (CNS), specifically on the surface of myelinating oligodendrocytes and external lamellae of myelin sheath. Although MOG protein constitutes only 0.01-0.05% of the CNS myelin proteins, it was demonstrated that MOG protein is a crucial autoantigen for multiple sclerosis in humans and experimental autoimmune encephalomyelitis (EAE) in rodents and monkeys (1-6).

AnaSpec is pleased to be the first in the industry to provide a whole suite of reagents and assay kits for the advancement of MS research. This includes MOG proteins, peptides, antibodies and assay kits.

MOG Proteins
These proteins, with sequences corresponding to human, mouse and rat extracellular domain, together with a 6x His tag were expressed in E. coli and purified from urea denatured bacterial lysate. The molecular weight found in all 3 recombinant proteins was 14.23 kDa. These proteins were shown to induce EAE in either mouse (for the human and mouse rMOGs) or rat (for rat rMOG).

MOG (35-55) and other MOG Peptide Fragments
AnaSpec’s MOG (35-55) peptide from mouse and rat sequence (cat# 60130) was shown to induce anti-MOG (35-55) autoantibody production in C57BL/6 mice at 100% incidence (10/10); providing quantitative data that this peptide is suitable for in vivo anti-MOG (35-55) autoantibody study. A cysteine-containing MOG (35-55) peptide induced polyclonal anti-MOG (35-55) antibody production in rabbits with high specificity, high affinity, and high titer indicating its high purity, as well as suitability for use in peptide-coated ELISA and Western blot. This mouse/rat MOG (35-55) peptide was used as a coating peptide to develop the industry’s first anti-MOG (35-55) ELISA kit for EAE study. The detection limit of the kit was determined to reach as low as 50 pg of anti-MOG (35-55) autoantibody in serum or cerebrospinal fluid. Lot to lot variability of the MOG (35-55) was found to be minimal.

MOG Antibodies
Two rabbit polyclonal antibodies towards the MOG extracellular domain are available; one raised against the human recombinant protein (cat# 55158) and the other against the mouse recombinant protein (cat# 55150). These Protein A affinity purified antibodies recognized a 27kDa band.

SensoLyte® Anti-MOG IgG ELISA Assay Kits

The SensoLyte Anti-Human MOG (1-125) IgG Quantitation ELISA Kit, SensoLyte Anti-Mouse MOG (1-125) and SensoLyteÒ Anti-Rat MOG (1-125) IgG ELISA assay kits are useful for determining the amount of anti-human MOG (1-125), anti-mouse MOG (1-125) and anti-rat MOG (1-125) antibodies, respectively. These kits, as well as the recombinant MOG (1-125) proteins are examples of innovative products from AnaSpec.

The SensoLyte® Anti-MOG (35-55) IgG Quantitative ELISA kits are optimized to detect anti-MOG (35-55) mouse/rat IgG and IgG subtypes. Using strips pre-coated with MOG (35-55) peptide and pre-blocked with BSA, the amount of anti-MOG IgG subtypes in serum or cerebrospinal fluid can be determined by ELISA and the absorbance read at 450 nm.

References:
1. Linares, D. et al. Protein Expression and Purif. 34, 249 (2004).
2. Bettadapura, J. et al. J. Neurochem. 70, 1593 (1998).
3. Oliver, AR. et al J. Immunol. 171, 462 (2003).
4. Von Budingen, H-C. et al. J. Clin. Immunol. 21, 155 (2001).
5. Lyons, J-A. et.al. Eur. J. Immunol. 29, 3432 (1999).
6. Von Budingen, H-C. et.al. Eur. J. Immunol. 34, 2072 (2003).

About AnaSpec

AnaSpec is a leading provider of integrated proteomics solutions to the world’s largest biotech, pharmaceutical, and academic research institutions. With a vision for innovation through synergy, AnaSpec focuses on three core technologies: peptides, detection reagents, and antibodies.

For more information visit www.anaspec.com

###
Contact Information
AnaSpec, Inc.
Ping Yang
408-452-5055
Contact
www.anaspec.com

Click here to view the list of recent Press Releases from AnaSpec, EGT Group
Promote Your Business